Yi Bi

TL;DR: H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs and demonstrates robust reversal activity against MDR in vitro and in vivo.

TL;DR: Cellular mechanism studies elucidated that 34b disrupted cell microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and depolarized mitochondria of K562 cells, suggesting that 27c and 34b deserve further research as potent antitumor agents for cancer therapy.

TL;DR: Compound 16f significantly inhibited tumor growth in H22 xenograft models without apparent toxicity, which was stronger than the reference compound CA-4, indicating that it is worthy to investigate 16f as a potent microtubule-destabilizing agent for cancer therapy.

TL;DR: A novel class of ocotillol-type triterpenoid derivatives have been synthesized and evaluated for their in-vitro antibacterial activity against several representative pathogenic bacterial strains.

TL;DR: A consensus model based on the predicted values of individual LLL models of LD50 is developed, yielding correlation coefficients R2 of 0.712 on a test set containing 2,896 compounds.